Encapsulation of the HSP-90 Chaperone Inhibitor 17-AAG in Stable Liposome Allow Increasing the Therapeutic Index as Assessed, in vitro, on Leishmania (L) amazonensis Amastigotes-Hosted in Mouse CBA Macrophages

The current long-term treatment for leishmaniasis causes severe side effects and resistance in some cases. An evaluation of the anti-leishmanial potential of an HSP90-inhibitor, 17-allylamino-17-demethoxygeldanamycin (17-AAG), demonstrated its potent effect against Leishmania spp. in vitro and in vi...

Full description

Bibliographic Details

Published in:	Frontiers in Cellular and Infection Microbiology
Main Authors:	Antonio Luis de Oliveira Almeida Petersen, Thiers A. Campos, Diana Angélica dos Santos Dantas, Juliana de Souza Rebouças, Juliana Cruz da Silva, Juliana P. B. de Menezes, Fábio R. Formiga, Janaina V. de Melo, Giovanna Machado, Patrícia S. T. Veras
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2018-08-01
Subjects:	17-AAG Tanespimicyn 2-hydroxypropyl-β-cyclodextrin liposome drug delivery systems leishmaniasis
Online Access:	https://www.frontiersin.org/article/10.3389/fcimb.2018.00303/full